Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (3099)	12/3/1997 3:40:00 PM
From: Andrew H	Read Replies (1) of 6136

>>Margie, there are NO later stage products! Even Pavlov's dogs could do more than one trick. Wake up.<< David, you are being unfair here. Even if the company has no value in their pipeline at all (which is certainly not the fact you say it is), the one trick is worth about $500M/year in revenues. Most biotechs would kill for that. This revenue will enable the company to buy promising products as well as whole biotech companies. The future for AGPH is nowhere near as bleak as you paint. What have you got against AGPH?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next